← Lundbeck (HLUYY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Lundbeck (HLUYY)
Healthcare · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-07-06 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
2
next 90d+
Dossier
Not yet
generate it
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
The catalyst path
- 2027-07-06 (est.)Phase 3 · Eptinezumabimp 9/10
- 2027-08-10 (est.)Phase 2 · Lu AG13909imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Vortioxetine (Lu AA21004) | Phase 3 | Major Depressive Disorder |
| Lu AG09222 | Phase 2 | Migraine |
| Lu AF82422 | Phase 3 | Multiple System Atrophy |
| Desmoteplase | Phase 3 | Acute Ischemic Stroke |
| Adjunct brexpiprazole | Phase 3 | Major Depression Disorder |
| ADT | Phase 3 | Major Depressive Disorder |
| Sertindole | Phase 3 | Schizophrenia |
| Intravenous Carbamazepine (IV CBZ) | Phase 3 | Epilepsy |
| Brexpiprazole | Phase 3 | Schizophrenia |
| MK0928, gaboxadol | Phase 3 | Insomnia |
| Nalmefene | Phase 3 | Alcohol Dependence |
| Clobazam Medium Dose | Phase 3 | Epilepsy |
| Clobazam | Phase 3 | Lennox-Gastaut Syndrome |
| Lu AA24530 | Phase 2 | Major Depressive Disorder |
| gaboxadol | Phase 3 | Insomnia |
| rasagiline | Phase 3 | Parkinson's Disease |
| Eptinezumab | Phase 3 | Chronic Migraine in Children |
| Zicronapine | Phase 3 | Schizophrenia |
| Idalopirdine | Phase 3 | Alzheimer's Disease |
| Vortioxetine | Phase 3 | Depressive Disorder, Major |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HLUYY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.